Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX
Syndax Pharmaceuticals — Q1 2025 Earnings Presentation
15 slides from Syndax Pharmaceuticals's earnings presentation, May 5, 2025
Slide 1: First Quarter 2025 Financial Results Presentation
First Quarter 2025 Financial Results Presentation / May 5, 2025
Slide 2: Forward-looking statements disclosure
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci
Slide 3: Syndax is executing as a commercial company with two first-in-class drugs
Syndax is executing as a commercial company with two first-in-class drugs Recent achievements • $20.0 M in Revuforj net revenue in 1Q25 • $13.6 M in Niktimvo net revenue in 1Q25 (reported by Incyte) Strong commercial execution • Results driven by high unmet need, compelling product profiles, and exc
Slide 4: Syndax is well-positioned to win in menin inhibition, building on a history of 'firsts'
Syndax is well-positioned to win in menin inhibition, building on a history of ‘firsts’ with revumenib Completed milestone First to receive FDA Q2 2025 approval for R/R Anticipated milestone mNPM1 AML First to submit sNDA for R/R mNPM1 AML 2024 under RTOR First and only 2023 FDA approved menin inhib
Slide 5: Strong first full quarter Revuforj results reflect high unmet need and excellent execution
Strong first full quarter Revuforj results reflect high unmet need, excellent commercial execution, and best-in-class profile Revuforj quarterly net revenue Revenue drivers: $20.0 M • Compelling product profile • Continued expansion of the breadth and depth of prescribing • Strong number of new pati
Slide 6: Continued expansion of breadth and depth of Revuforj prescribing and formulary coverage
Continued expansion of breadth and depth of Revuforj prescribing and formulary coverage ACCOUNTS MARKET ACCESS High priority (Tier 1/Tier 2) accounts ordering Managed care lives with formulary coverage 100% 44% 80% 72% 33% 60% 53% 40% 30% 20% 7% 0% 0% End of Feb '25 End of Mar '25 Nov '24 Dec '24 Ja
Slide 7: Revuforj strategic launch imperatives
Revuforj strategic launch imperatives 1 Leave no appropriate patient behind 2 Engage all key stakeholders First-in-class menin inhibitor FDA approved for the treatment of relapsed or refractory acute 3 leukemia with a KMT2A translocation in adult and pediatric patients one year and older Deliver bes
Slide 8: Strong initial U.S. launch of Niktimvo, driven by high unmet need
Strong initial U.S. launch of Niktimvo, driven by high unmet need and excellent commercial execution by Syndax and Incyte 1Q25 NIKTIMVO NET REVENUE RESULTS REFLECT: REPORTED BY INCYTE ✓ High unmet patient need $13.6 M ✓ Unique product profile in first ~two months of U.S. launch ✓ Strong product awar
Slide 9: Encouraging early adoption of Niktimvo and market access in the U.S.
Encouraging early adoption of Niktimvo and market access in the U.S. PATIENTS ACCOUNTS ACCESS AS OF THE END OF MARCH ‘25 ~95% >1,250 of top accounts ordered J9038 infusions YTD J-code assigned >70% effective 4/1/25 of all BMTs ordered 9 BMTs, bone marrow transplant centers
Slide 10: Niktimvo strategic launch imperatives
Niktimvo strategic launch imperatives 1 Target high-potential transplant centers First-in-class anti-CSF-1R-blocking antibody 2 FDA approved for treatment of chronic GVHD after failure Establish Niktimvo as a differentiated option of at least two prior lines of systemic therapy in adult and pediatri
Slide 11: Aggressively advancing a robust clinical development strategy
Aggressively advancing a robust clinical development strategy Revumenib (select trials) Ph 1 or Ph 2 Ph 2 or Ph 3 Registration Approved Milestones AUGMENT-101 (rev in R/R KMT2Ar acute leukemia) U.S. launch underway AUGMENT-101 (rev in R/R mNPM1 AML) Submitted sNDA R/R AUGMENT-102 (rev + IC in R/R mN
Slide 12: Financial highlights: 1Q25
Financial highlights: 1Q25 Key 1Q25 Financial Results (Unaudited) Three Months Ended March 31 (in millions) 2025 2024 AS OF MARCH 31, 2025: Product revenue 20.0 - Collaboration revenue - - $602.1 M Milestone & license revenue - - in cash and equivalents2 Total revenue $20.0 - Cost of product sales (
Slide 13: Expected upcoming milestones
Revuforj (revumenib) Menin-KMT2A inhibition • Maximize U.S. adoption of Revuforj as the preferred menin inhibitor • Publication of pivotal R/R mNPM1 AML data expected imminently, followed by immediate submission to clinical guidelines • Anticipated approval of sNDA for R/R mNPM1 AML • Report Ph 1 da
Slide 14: Fueled by a passion for patients
FUELED BY A PASSION FOR PATIENTS Lilah, diagnosed with R/R AML 14
Slide 15: Slide 15
Syndax Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix